Side Effect Management
San Diego, CA—The investigational proteasome inhibitor MLN9708 is the first oral drug in this class to enter clinical trials in multiple myeloma. Although development is still in the early stages, interest in this agent is very high.
Over the past decade, the use of bortezomib, lenalidomide, and thalidomide, with or without autologous stem cell transplant, has significantly im proved outcomes for patients with multiple myeloma (MM). Several of the regimens now listed as category 1 recommendations by the National Comprehensive Cancer Network (NCCN) for the treatment of MM include 1 or more of these agents.1 Category 1 designation refers to uniform NCCN consensus that the intervention is appropriate based on high-level evidence.
Myeloma-related bone disease is devastating for patients, and can have a tremendous impact on performance status and quality of life.1 It has also been reported that in patients with certain types of malignancies, including myeloma, pathologic fractures correlate with reduced survival.2 Fortunately, the introduction of potent bisphosphonate therapy, with such agents as zoledronic acid and pamidronate, has revolutionized the treatment of bone disease in patients with multiple myeloma (MM).
Results 1 - 8 of 8